| Literature DB >> 16835060 |
Dhelia M Williamson1, Mary C White, Charles Poole, David Kleinbaum, Robert Vogt, Kari North.
Abstract
Residents living in communities near Superfund sites have expressed concern that releases from these facilities affect their health, including adverse effects on their immune systems. We used data from six cross-sectional studies to evaluate whether people who live near several Superfund sites are more likely to have individual immunoglobulin test results (IgA, IgG, and IgM) below or above the reference range than those who live in comparison areas with no Superfund site. Study participants consisted of target-area residents who lived close to a Superfund site and comparison-area residents who were not located near any Superfund or hazardous waste sites. A consistent modeling strategy was used across studies to assess the magnitude of the relationship between area of residence and immunoglobulin test results, adjusting for potential confounders and effect modifiers. In all study areas, the results suggest that people who live near a Superfund site may have been more likely to have IgA test results above the reference range than comparison areas residents regardless of modeling strategy employed. The effect measures were larger for residents who lived in communities near military bases with groundwater contamination. For all analyses the wide confidence intervals reflect uncertainty in the magnitude of these effects. To adequately address the question of whether the immune system is affected by low-level exposures to hazardous substances, we recommend that more functional immunotoxicity tests be conducted in human populations where individual exposure information is available or when it can be reasonably estimated from environmental exposure measurements.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16835060 PMCID: PMC1513332 DOI: 10.1289/ehp.8946
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
ATSDR cross-sectional studies that included the standardized questionnaire and immune biomarker panel, 1991–1994.
| Study location | Type of facility | Exposure pathway | Contaminants |
|---|---|---|---|
| McClellan Air Force Base, Sacramento, CA | Aircraft maintenance facility | Ambient air, sediment, soil, groundwater | Volatile organic compounds, heavy metals |
| Calvert City Industrial Complex, Calvert City, KY | Manufacturing and handling of chemical compounds | Ambient air | Heavy metals, volatile organic compounds, mineral acids, asbestos, dioxin, radioactive substances, neurotoxic chemicals |
| Otis Air National Guard, Falmouth, MA | Military training installation | Groundwater | Volatile organic compounds, polychlorinated biphenyls, polycyclic aromatic hydrocarbons |
| Cornhusker Army Ammunition Plant, Cornhusker, NE | Production of artillery shells, bombs, and rockets | Groundwater | Explosives (RDX and TNT), volatile organic compounds |
| Caldwell Systems Inc., Caldwell County, NC | Hazardous waste incinerator | Ambient air | Incineration products, phthalates, volatile organic compounds, chromium, arsenic |
| Brio Refining Co. Inc., Harris County, TX | Regeneration of copper catalysts, recovery of petrochemicals and vinyl chloride | Groundwater | Volatile organic compounds, organic compounds |
Abbreviations: RDX, royal demolition explosives (1,3,5-trinitro-1,3,5-triazine); TNT, trinitrotoluene.
Demographic characteristics of study participants from six cross-sectional studies conducted by ATSDR, 1991–1994 [n (%)].
| California ( | Kentucky ( | Massachusetts ( | Nebraska ( | North Carolina ( | Texas ( | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( |
| Age | ||||||||||||
| < 10 | 11 (2) | 8 (4) | 11 (3) | 12 (3) | 20 (3) | 10 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 17 (4) | 17 (5) |
| 10–19 | 123 (27) | 50 (25) | 62 (17) | 73 (20) | 125 (21) | 67 (22) | 77 (26) | 61 (20) | 12 (7) | 2 (2) | 77 (19) | 89 (25) |
| 20–29 | 54 (12) | 19 (9) | 43 (12) | 37 (10) | 45 (7) | 15 (5) | 19 (6) | 6 (2) | 24 (15) | 9 (10) | 58 (14) | 55 (15) |
| 30–39 | 64 (14) | 36 (18) | 65 (18) | 70 (19) | 118 (20) | 59 (19) | 12 (4) | 21 (7) | 20 (12) | 12 (13) | 147 (36) | 128 (36) |
| 40–49 | 69 (15) | 33 (16) | 60 (17) | 54 (15) | 114 (19) | 61 (20) | 76 (26) | 70 (23) | 44 (27) | 29 (31) | 61 (15) | 43 (12) |
| 50–59 | 58 (13) | 20 (10) | 46 (13) | 51 (14) | 76 (13) | 39 (13) | 66 (22) | 74 (25) | 32 (20) | 23 (24) | 41 (10) | 15 (4) |
| ≥ 60 | 74 (16) | 36 (18) | 70 (20) | 66 (18) | 107 (18) | 56 (18) | 47 (16) | 68 (23) | 32 (20) | 19 (20) | 13 (3) | 13 (4) |
| Sex | ||||||||||||
| Male | 219 (48) | 102 (50) | 168 (47) | 180 (50) | 290 (48) | 147 (48) | 152 (51) | 144 (48) | 76 (46) | 42 (45) | 203 (49) | 176 (49) |
| Female | 234 (52) | 100 (50) | 189 (53) | 183 (50) | 315 (52) | 160 (52) | 145 (49) | 156 (52) | 88 (54) | 52 (55) | 211 (51) | 184 (51) |
| Race | ||||||||||||
| White | 385 (85) | 182 (90) | 353 (99) | 361 (99) | 576 (95) | 296 (96) | 287 (97) | 297 (99) | 164 (100) | 94 (100) | 241 (58) | 214 (59) |
| African American | 19 (4) | 3 (1) | 1 (< 1) | 0 (0) | 8 (1) | 2 (1) | 1 (< 1) | 1 (< 1) | 0 (0) | 0 (0) | 54 (13) | 48 (13) |
| Other | 49 (11) | 16 (8) | 2 (1) | 2 (1) | 20 (3) | 9 (3) | 7 (2) | 2 (1) | 0 (0) | 0 (0) | 78 (19) | 79 (22) |
| Unknown/missing | 0 (0) | 1 (< 1) | 1 (< 1) | 0 (0) | 1 (< 1) | 0 (0) | 2 (< 1) | 0 (0) | 0 (0) | 0 (0) | 41 (10) | 19 (5) |
| Hispanic ethnicity | ||||||||||||
| Yes | 67 (15) | 30 (15) | 5 (1) | 5 (1) | 10 (2) | 2 (1) | 3 (1) | 10 (3) | 0 (0) | 0 (0) | 65 (16) | 81 (23) |
| No | 381 (84) | 172 (85) | 346 (97) | 357 (98) | 592 (98) | 304 (99) | 293 (99) | 289 (96) | 0 (0) | 0 (0) | 346 (84) | 267 (74) |
| Missing | 5 (1) | 0 (0) | 6 (2) | 1 (< 1) | 3 (< 1) | 1 (< 1) | 1 (< 1) | 1 (< 1) | 164 (100) | 94 (100) | 3 (1) | 12 (3) |
| Education | ||||||||||||
| < High school | 205 (45) | 79 (39) | 107 (30) | 121 (33) | 154 (25) | 75 (24) | 81 (27) | 75 (25) | 60 (37) | 25 (27) | 115 (28) | 133 (37) |
| High school | 109 (24) | 55 (27) | 128 (36) | 128 (35) | 289 (48) | 149 (49) | 122 (41) | 106 (35) | 45 (27) | 31 (33) | 200 (48) | 166 (46) |
| > High school | 139 (31) | 68 (34) | 121 (34) | 114 (31) | 162 (27) | 83 (27) | 94 (32) | 119 (40) | 59 (36) | 38 (40) | 98 (24) | 61 (17) |
| Unknown/missing | 0 (0) | 0 (0) | 1 (< 1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (< 1) | 0 (0) |
| Years in residence | ||||||||||||
| < 5 | 102 (23) | 95 (47) | 117 (33) | 136 (37) | 74 (12) | 32 (10) | 0 (0) | 0 (0) | 26 (16) | 10 (11) | 252 (61) | 210 (58) |
| 5–10 | 91 (20) | 44 (22) | 90 (25) | 79 (22) | 197 (33) | 111 (36) | 0 (0) | 0 (0) | 34 (21) | 21 (22) | 137 (33) | 110 (31) |
| 10–19 | 161 (36) | 36 (18) | 84 (24) | 90 (25) | 274 (45) | 139 (45) | 247 (83) | 189 (63) | 54 (33) | 30 (32) | 25 (6) | 40 (11) |
| ≥ 20 | 99 (22) | 27 (13) | 66 (18) | 58 (16) | 60 (10) | 25 (8) | 50 (17) | 111 (37) | 50 (30) | 33 (35) | 0 (0) | 0 (0) |
Comp, comparison group.
Self-reported symptoms and illnesses, responses to subjective questions, and other exposure information from six cross-sectional studies conducted by ATSDR 1991–1994 [n (%)].
| California ( | Kentucky ( | Massachusetts ( | Nebraska ( | North Carolina ( | Texas ( | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( |
| Symptoms/Illnesses | ||||||||||||
| Eczema or skin rashes | ||||||||||||
| Yes | 103 (23) | 29 (14) | 36 (10) | 43 (12) | 86 (14) | 43 (14) | 49 (16) | 38 (13) | 35 (21) | 19 (20) | 114 (28) | 44 (12) |
| No | 350 (77) | 173 (86) | 321 (90) | 320 (88) | 519 (86) | 264 (86) | 248 (84) | 262 (87) | 129 (79) | 75 (80) | 300 (72) | 316 (88) |
| Asthma or bronchitis | ||||||||||||
| Yes | 23 (5) | 6 (3) | 11 (3) | 11 (3) | 12 (2) | 6 (2) | 10 (3) | 7 (2) | 23 (14) | 4 (4) | 12 (3) | 5 (1) |
| No | 430 (95) | 196 (97) | 346 (97) | 352 (97) | 593 (98) | 301 (98) | 287 (97) | 293 (98) | 141 (86) | 90 (96) | 402 (97) | 355 (99) |
| Allergy | ||||||||||||
| Yes | 220 (49) | 71 (35) | 104 (29) | 104 (29) | 204 (34) | 81 (26) | 119 (40) | 100 (33) | 86 (52) | 43 (46) | 164 (40) | 83 (23) |
| No | 233 (51) | 131 (65) | 253 (71) | 259 (71) | 401 (66) | 226 (74) | 178 (60) | 200 (67) | 78 (48) | 51 (54) | 250 (60) | 277 (77) |
| Cancer/immune system | ||||||||||||
| Yes | 61 (13) | 22 (11) | 36 (10) | 43 (12) | 86 (14) | 43 (14) | 49 (16) | 38 (13) | 41 (25) | 22 (23) | 35 (8) | 14 (4) |
| No | 392 (87) | 180 (89) | 321 (90) | 320 (88) | 519 (86) | 264 (86) | 248 (84) | 262 (87) | 123 (75) | 72 (77) | 379 (92) | 346 (96) |
| Other Information | ||||||||||||
| Overall health | ||||||||||||
| Excellent | 100 (22) | 61 (30) | 114 (32) | 110 (30) | 260 (43) | 142 (46) | 107 (36) | 106 (35) | 15 (9) | 12 (13) | 109 (26) | 116 (32) |
| Good | 230 (51) | 104 (51) | 190 (53) | 210 (58) | 300 (50) | 141 (46) | 166 (56) | 173 (58) | 92 (56) | 63 (67) | 244 (59) | 181 (50) |
| Fair | 101 (22) | 31 (15) | 45 (13) | 39 (11) | 40 (7) | 21 (7) | 23 (8) | 20 (7) | 47 (29) | 16 (17) | 58 (14) | 61 (17) |
| Poor | 22 (5) | 6 (3) | 7 (2) | 4 (1) | 4 (< 1) | 3 (1) | 1 (< 1) | 1 (< 1) | 10 (6) | 3 (3) | 2 (< 1) | 2 (1) |
| Missing | 0 (0) | 0 (0) | 1 (< 1) | 0 (0) | 1 (< 1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (< 1) | 0 (0) |
| Heat home | ||||||||||||
| Yes | NA | NA | 110 (31) | 120 (33) | NA | NA | 116 (39) | 64 (21) | 95 (58) | 51 (54) | NA | NA |
| No | 247 (69) | 243 (67) | 181 (61) | 236 (79) | 69 (42) | 43 (46) | ||||||
| Occupational exposure | ||||||||||||
| Yes | NA | NA | 184 (52) | 210 (58) | NA | NA | 136 (46) | 116 (39) | 117 (71) | 57 (61) | NA | NA |
| No | 173 (48) | 153 (42) | 161 (54) | 184 (61) | 47 (29) | 37 (39) | ||||||
| Currently smoke | ||||||||||||
| Yes | 102 (23) | 40 (20) | 89 (25) | 100 (28) | 101 (17) | 61 (20) | 41 (14) | 47 (16) | 54 (33) | 27 (29) | 80 (19) | 37 (10) |
| No | 309 (68) | 134 (66) | 242 (68) | 232 (64) | 453 (75) | 220 (72) | 249 (84) | 245 (82) | 110 (67) | 67 (71) | 330 (80) | 321 (89) |
| Missing | 42 (9) | 28 (14) | 26 (7) | 31 (8) | 51 (8) | 26 (8) | 7 (2) | 8 (2) | 0 (0) | 0 (0) | 4 (1) | 2 (1) |
| Someone smoke in house | ||||||||||||
| Yes | 134 (30) | 54 (27) | 100 (28) | 117 (32) | 130 (21) | 69 (22) | 62 (21) | 77 (26) | 56 (34) | 24 (26) | 117 (28) | 88 (24) |
| No | 277 (61) | 120 (59) | 230 (64) | 215 (59) | 424 (70) | 213 (69) | 228 (77) | 215 (72) | 108 (66) | 70 (74) | 295 (71) | 269 (75) |
| Missing | 42 (9) | 28 (14) | 27 (8) | 31 (9) | 51 (8) | 25 (8) | 7 (2) | 8 (2) | 0 (0) | 0 (0) | 2 (1) | 3 (1) |
Abbreviations: Comp, comparison group; NA, not applicable.
Onset since moving to current home.
Includes allergy, hay fever, watery and burning eyes, irritated nose, severe headaches; onset since moving to current home.
Includes all cancer types, lupus, osteoarthritis, multiple sclerosis, etc.
Use of coal stove, fireplace, kerosene or gas heater, or wood stove to heat house.
Occupational exposures to solvents, cleaning agents, dust, insulating materials, paints, gasoline, or kerosene.
Serum immunoglobulin results from six cross-sectional studies conducted by ATSDR 1991–1994 [n (%)].
| California ( | Kentucky ( | Massachusetts ( | Nebraska ( | North Carolina ( | Texas ( | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( | Target ( | Comp ( |
| IgA | ||||||||||||
| Below | 11 (2) | 3 (1) | 13 (4) | 8 (2) | 14 (2) | 9 (3) | 7 (2) | 14 (5) | 11 (7) | 5 (5) | 8 (2) | 5 (1) |
| Within | 420 (93) | 191 (95) | 333 (93) | 346 (95) | 558 (92) | 282 (92) | 281 (95) | 279 (93) | 143 (87) | 85 (90) | 379 (92) | 326 (91) |
| Above | 17 (4) | 7 (3) | 11 (3) | 9 (2) | 25 (4) | 5 (2) | 9 (3) | 5 (2) | 4 (2) | 4 (4) | 16 (4) | 10 (3) |
| Missing | 5 (1) | 1 (< 1) | 0 (0) | 0 (0) | 8 (1) | 11 (4) | 0 (0) | 2 (< 1) | 6 (4) | 0 (0) | 11 (3) | 19 (5) |
| IgG | ||||||||||||
| Below | 2 (< 1) | 4 (2) | 5 (1) | 3 (1) | 11 (2) | 14 (5) | 9 (3) | 6 (2) | 4 (2) | 1 (1) | 7 (2) | 5 (1) |
| Within | 433 (96) | 185 (92) | 342 (96) | 356 (98) | 571 (94) | 276 (90) | 282 (95) | 287 (96) | 150 (92) | 93 (99) | 368 (89) | 321 (89) |
| Above | 13 (3) | 12 (6) | 10 (3) | 4 (1) | 15 (2) | 6 (2) | 6 (2) | 5 (2) | 4 (2) | 0 (0) | 28 (7) | 15 (4) |
| Missing | 5 (1) | 1 (< 1) | 0 (0) | 0 (0) | 8 (1) | 11 (4) | 0 (0) | 2 (< 1) | 6 (4) | 0 (0) | 11 (3) | 19 (5) |
| IgM | ||||||||||||
| Below | 1 (< 1) | 3 (1) | 3 (1) | 3 (1) | 6 (1) | 1 (< 1) | 6 (2) | 3 (1) | 0 (0) | 2 (2) | 10 (2) | 2 (1) |
| Within | 432 (95) | 188 (93) | 342 (96) | 350 (96) | 567 (94) | 282 (92) | 278 (94) | 282 (94) | 149 (91) | 88 (94) | 380 (92) | 320 (89) |
| Above | 15 (3) | 10 (5) | 12 (3) | 10 (3) | 24 (4) | 13 (4) | 13 (4) | 13 (4) | 9 (5) | 4 (4) | 13 (3) | 19 (5) |
| Missing | 5 (1) | 1 (< 1) | 0 (0) | 0 (0) | 8 (1) | 11 (4) | 0 (0) | 2 (< 1) | 6 (4) | 0 (0) | 11 (3) | 19 (5) |
| One or more | ||||||||||||
| Below | 11 (2) | 8 (4) | 18 (5) | 12 (3) | 24 (4) | 19 (6) | 18 (6) | 18 (6) | 12 (7) | 7 (7) | 24 (6) | 10 (3) |
| Within | 395 (87) | 167 (83) | 310 (87) | 329 (91) | 514 (85) | 254 (83) | 252 (85) | 258 (86) | 129 (79) | 79 (84) | 334 (81) | 289 (80) |
| Above | 42 (9) | 26 (13) | 29 (8) | 22 (6) | 59 (10) | 23 (7) | 27 (9) | 22 (7) | 17 (10) | 8 (9) | 45 (11) | 42 (12) |
| Missing | 5 (1) | 1 (< 1) | 0 (0) | 0 (0) | 8 (1) | 11 (4) | 0 (0) | 2 (< 1) | 6 (4) | 0 (0) | 11 (3) | 19 (5) |
Comp, comparison group.
OR estimates (95% CIs) for area of residence and IgA test results for six ATSDR studies conducted 1991–1994.
| Study area | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
|---|---|---|---|---|---|
| Results below the reference range | |||||
| California | 1.67 (0.46–6.05) | 2.05 (0.54–7.88) | 1.92 (0.48–7.68) | 2.17 (0.52–9.09) | 2.66 (0.52–13.51) |
| Kentucky | 1.69 (0.69–4.13) | 1.65 (0.67–4.08) | 1.27 (0.49–3.28) | 1.29 (0.49–3.37) | 1.36 (0.54–3.44) |
| Massachusetts | 0.79 (0.34–1.84) | 0.80 (0.34–1.88) | 0.65 (0.26–1.57) | 0.65 (0.26–1.59) | 0.63 (0.26–1.52) |
| Nebraska | 0.50 (0.20–1.25) | 0.60 (0.23–1.56) | 0.58 (0.22–1.57) | 0.59 (0.21–1.62) | 1.29 (0.06–27.8) |
| North Carolina | 1.31 (0.44–3.89) | ||||
| Texas | 1.38 (0.45–4.25) | 0.98 (0.28–3.44) | 1.15 (0.32–4.18) | 0.83 (0.20–3.47) | 1.16 (0.35–3.88) |
| Results above the reference range | |||||
| California | 1.10 (0.45–2.71) | 1.35 (0.51–3.62) | 1.32 (0.49–3.53) | 1.22 (0.45–3.36) | 1.17 (0.47–2.91) |
| Kentucky | 1.27 (0.52–3.10) | 1.21 (0.49–3.0) | 1.13 (0.45–2.84) | 1.27 (0.50–3.25) | 1.22 (0.49–3.03) |
| Massachusetts | 2.53 (0.96–6.67) | 2.46 (0.92–6.54) | 2.24 (0.83–6.01) | 2.41 (0.88–6.63) | 11.29 (0.11–145.53) |
| 1.66 (0.40–6.83) | |||||
| 0.14 (0.0–4.52) | |||||
| 1.66 (0.40–6.83) | |||||
| Nebraska | 1.79 (0.59–5.40) | 2.13 (0.58–7.77) | 2.02 (0.54–7.61) | 1.95 (0.46–8.21) | 1.69 (0.56–5.15) |
| North Carolina | |||||
| Texas | 1.38 (0.62–3.07) | 1.23 (0.52–2.91) | 1.32 (0.56–3.13) | 1.71 (0.69–4.23) | 1.62 (0.71–3.69) |
, OR estimates could not be calculated.
Model 1: unadjusted.
Model 2: adjusted for age, sex, race, Hispanic ethnicity, educational level, years in residence.
Model 3: adjusted for the model 2 covariates and other exposure information.
Model 4: adjusted for the model 3 covariates, symptoms, illnesses, and overall health.
Model 5: adjusted using the backward elimination strategy of Kleinbaum (1994).
OR for women.
OR for men.
OR for individuals with allergies.
OR for individuals without allergies.
OR for smokers.
OR for nonsmokers.
OR estimates (95% CIs) for area of residence and IgM test results for six ATSDR studies conducted 1991–1994.
| Study area | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
|---|---|---|---|---|---|
| Results below the reference range | |||||
| California | |||||
| Kentucky | |||||
| Massachusetts | |||||
| Nebraska | |||||
| North Carolina | |||||
| Texas | |||||
| Results above the reference range | |||||
| California | 0.65 (0.29–1.48) | 0.66 (0.27–1.60) | 0.60 (0.24–1.52) | 0.60 (0.23–1.56) | 0.67 (0.28–1.62) |
| Kentucky | 1.23 (0.52–2.88) | 1.21 (0.51–2.90) | 1.23 (0.51–2.96) | 1.19 (0.48–2.95) | 1.18 (0.50–2.79) |
| Massachusetts | 0.92 (0.46–1.83) | 0.92 (0.45–1.89) | 0.90 (0.44–1.87) | 0.85 (0.41–1.76) | 0.92 (0.46–1.84) |
| Nebraska | 1.01 (0.46–2.23) | 1.22 (0.52–2.84) | 1.05 (0.44–2.51) | 1.0 (0.42–2.41) | 0.98 (0.44–2.17) |
| North Carolina | 1.33 (0.40–4.44) | ||||
| Texas | 0.58 (0.28–1.19) | 0.65 (0.30–1.43) | 0.68 (0.31–1.51) | 0.58 (0.25–1.38) | 0.62 (0.29–1.34) |
, adjusted OR estimates could not be calculated.
Model 1: unadjusted.
Model 2: adjusted for age, sex, race, Hispanic ethnicity, educational level, years in residence.
Model 3: adjusted for the model 2 covariates and other exposure information.
Model 4: adjusted for the model 3 covariates, symptoms, illnesses, and overall health.
Model 5: adjusted using the backward elimination strategy of Kleinbaum (1994).
OR estimates (95% CIs) for area of residence and IgG test results for six ATSDR studies conducted 1991–1994.
| Study area | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
|---|---|---|---|---|---|
| Results below the reference range | |||||
| California | |||||
| Kentucky | |||||
| Massachusetts | 0.38 (0.17–0.85) | 0.38 (0.17–0.86) | 0.40 (0.17–0.94) | 0.44 (0.18–1.06) | 0.43 (0.18–1.01) |
| Nebraska | 1.53 (0.54–4.34) | 1.43 (0.49–4.21) | 1.35 (0.44–4.17) | 1.31 (0.42–4.13) | 1.68 (0.58–4.85) |
| North Carolina | |||||
| Texas | 1.22 (0.38–3.89) | 1.83 (0.41–8.08) | 1.79 (0.38–8.53) | 1.68 (0.27–10.44) | 1.03 (0.28–3.80) |
| Results above the reference range | |||||
| California | 0.46 (0.21–1.03) | 0.38 (0.16–2.13) | 0.38 (0.15–0.96) | 0.35 (0.14–0.90) | 0.39 (0.16–0.94) |
| Kentucky | 2.60 (0.81–8.38) | 2.38 (0.70–8.06) | 2.39 (0.70–8.16) | 2.57 (0.73–9.07) | 2.51 (0.78–8.11) |
| Massachusetts | 1.21 (0.46–3.15) | 0.92 (0.34–2.50) | 0.72 (0.25–2.05) | 0.74 (0.25–2.14) | 0.90 (0.33–2.44) |
| Nebraska | 1.22 (0.37–4.05) | 1.26 (0.33–4.90) | 1.36 (0.34–5.50) | 1.02 (0.24–4.30) | 1.38 (0.41–4.66) |
| North Carolina | |||||
| Texas | 1.63 (0.85–3.10) | 1.52 (0.72–3.20) | 1.60 (0.75–3.41) | 1.52 (0.66–3.49) | 1.58 (0.82–3.04) |
, OR estimates could not be calculated.
Model 1: unadjusted.
Model 2: adjusted for age, sex, race, Hispanic ethnicity, educational level, years in residence.
Model 3: adjusted for the model 2 covariates and other exposure information.
Model 4: adjusted for the model 3 covariates, symptoms, illnesses, and overall health.
Model 5: adjusted using the backward elimination strategy of Kleinbaum (1994).